Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital
mi
from
Santa Rosa, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Innovative Clinical Research
mi
from
Whittier, CA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Innovative Clinical Research
mi
from
Whittier, CA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospitals
mi
from
Fort Lauderdale, FL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospitals
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Miami/Sylvester Cancer Center
mi
from
Miami, FL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Miami/Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
New Jersey Hematology Oncology Associates
mi
from
Brick, NJ
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery
Precision Medicine for Patients With Malignancy at the Comprehensive Cancer Center of Wake Forest University
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery
Precision Medicine for Patients With Malignancy at the Comprehensive Cancer Center of Wake Forest University
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Palo Verde Hematology & Oncology
mi
from
Glendale, AZ
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Palo Verde Hematology & Oncology
mi
from
Glendale, AZ
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Ucla Hematology/Oncology
mi
from
Los Angeles, CA
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Ucla Hematology/Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Research Medical Center
mi
from
Kansas City, MO
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
North Shore Hematology Oncology Associates
mi
from
East Setauket, NY
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
North Shore Hematology Oncology Associates
mi
from
East Setauket, NY
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Centre Leon Berard
mi
from
Lyon,
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Centre Leon Berard
mi
from
Lyon,
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Comprehensive Cancer Center
mi
from
New York, NY
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
mi
from
Camperdown,
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
mi
from
Camperdown,
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Scottsdale Healthcare /ID# 132963
mi
from
Scottsdale, AZ
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Scottsdale Healthcare /ID# 132963
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope /ID# 154053
mi
from
Duarte, CA
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope /ID# 154053
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
UC Davis Comp Cancer Ctr /ID# 154644
mi
from
Sacramento, CA
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
UC Davis Comp Cancer Ctr /ID# 154644
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Yale University /ID# 136982
mi
from
New Haven, CT
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Yale University /ID# 136982
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago /ID# 155453
mi
from
Chicago, IL
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago /ID# 155453
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana Univ School of Medicine /ID# 132946
mi
from
Indianapolis, IN
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana Univ School of Medicine /ID# 132946
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Duke Univ Medical Center /ID# 154647
mi
from
Durham, NC
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Duke Univ Medical Center /ID# 154647
mi
from
Durham, NC
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research /ID# 154059
mi
from
Dallas, TX
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research /ID# 154059
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Univ TX, MD Anderson /ID# 132276
mi
from
Houston, TX
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Univ TX, MD Anderson /ID# 132276
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center /ID# 164122
mi
from
Houston, TX
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center /ID# 164122
mi
from
Houston, TX
Click here to add this to my saved trials
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
San Juan Oncology Associates
mi
from
Farmington, NM
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
San Juan Oncology Associates
mi
from
Farmington, NM
Click here to add this to my saved trials
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Research
mi
from
Oklahoma City, OK
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northwest
mi
from
Portland, OR
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northwest
mi
from
Portland, OR
Click here to add this to my saved trials
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Lancaster Cancer Center
mi
from
Lancaster, PA
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Lancaster Cancer Center
mi
from
Lancaster, PA
Click here to add this to my saved trials